References:
1)
Brothwell, D.R. (1963). Digging up Bones; the
Excavation, Treatment and Study of Human Skeletal Remains (pp 126). London, UK: British Museum
(Natural History).
2) Seigworth, G.S. (1980). Bloodletting Over the Centuries. New York, USA: New York State
Journal of Medicine.
3) Millon, T. (2004). Masters of the mind. Hoboken, NJ,
US: John Wiley & Sons, Inc.
4) Porter, R. (1997) History
Today (pp.41–8).
5) Andrews, J.; Briggs, A.;
Porter, R.; Tucker, P.; Waddington, K. The History of Bethlem (1997).
London & New York: Routledge.
6) Cavell, M. (2006). Becoming
a Subject: Reflections in Philosophy and Psychoanalysis. New
York: Oxford University Press.
7)
Bovet, D. (1950). Introduction to
antihistamine agents and antergan derivatives (pp. 1089). New York, USA: Academy of Science.
8)
National Cancer Institute: PDQ®
Cannabis and Cannabinoids (n.d.). Retrieved March 28, 2013, from
http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional.
9)
Treatment Advocacy Center. (n.d.).
(2010, May). More Mentally Ill Persons
Are in Jails and Prisons Than Hospitals: A Survey of the States. Retrieved
from http://
http://www.treatmentadvocacycenter.org/storage/documents/final_jails_v_hospitals_study.pdf.
10)
Department of Health and Human Services. Mental
Illness Surveillance Among Adults in the United States (n.d.). Retrieved March 28, 2013,
from http://www.cdc.gov/mmwr/preview/mmwrhtml/su6003a1.htm#Tab2.
11)
Merikangas, K.R., He, J., Burstein, M., Swanson,
S., Avenevoli, S., Cui, L., Benjet, C., Georgiades, K., & Swendsen, J.
(2010). "Lifetime Prevalence of Mental Disorders in US Adolescents:
Results from the National Comorbidity Study-Adolescent Supplement (NCS-A)
(Electronic version). Journal of American Academic Child Adolescent Psychiatry,
49(10): 980–989. Published online July 31, 2010.
12) National Institute of Mental
Health (2013). Brain basics. Retrieved from
http://www.nimh.nih.gov/health/educational-resources/brain-basics/brain-basics.shtml
13) Karolinska Institutet (2010, May
19). Dopamine system in highly creative people similar to that seen in
schizophrenics, study finds.
14) American Association of
Neurological Surgeons (2006). Anatomy of the brain. Retrieved from http://www.aans.org/Patient%20Information/Conditions%20and%20Treatments/Anatomy%20of%20the%20Brain.aspx.
15) National
Brain Tumor Society (2013). Brain anatomy. Retrieved from http://www.braintumor.org/patients-family-friends/about-brain-tumors/brain-anatomy.html.
16) Purves, D., Augustine, G.J.,
& Fitzpatrick, D. (2001). Neuroglial cells.
Neuroscience (2nd edition). Sunderland, MA: Sinauer Associates.
Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK10869/.
17. Rughani, Anand.
(2013). Brain Anatomy.
Retrieved from http://emedicine.medscape.com/article/1898830-overview#a1.
18) University of
Maryland. Tetrodotoxin: Mode of action. Retrieved from
http://www.life.umd.edu/grad/mlfsc/zctsim/ionchannel.html.
19) National
Institute of Health. Information about
Mental Illness and the Brain. Retrieved from
http://science.education.nih.gov/supplements/nih5/mental/guide/info-mental-a.htm.
20) Synthesis and
Storage of Neurotransmitters. Williams College. Retrieved from
http://web.williams.edu/imput/synapse/pages/I.html.
21) Weiner, N. (1979). Multiple
factors regulating the release of norepinephrine consequent to nerve
stimulation. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/36304.
http://www.ncbi.nlm.nih.gov/pubmed/36304.
22) Best, J.A.,
Nijhout, F.H., & Reed, M.C. (2009). Homeostatic mechanisms in dopamine
synthesis and release: a mathematical model. Theoretical Biology and Medical
Modeling, 6(21). doi:10.1186.
1742-4682-6-21.
23) Purves, D.,
Augustine, G.J., & Fitzpatrick, D. (2001). Glutamate. Neuroscience (2nd
edition). Sunderland, MA: Sinauer Associates. Retrieved from
http://www.ncbi.nlm.nih.gov/books/NBK10807/.
24) Boerree, G.C.
(2009). General Psychology: Neurotransmitters. Shippensburg University.
Retrieved from http://webspace.ship.edu/cgboer/genpsyneurotransmitters.html.
25)
Riley, R.J., Parker, A.J., Trigg, S., & Manners, C.N. (2001). Development
of a generalized, quantitative physicochemical model of CYP3A4 inhibition for
use in early drug discovery. Pharmaceutical
Research, 18(5),652-5.
26)
Martinez, M.N. & Amidon, G.L. (2002). A mechanistic approach to
understanding the factors affecting drug absorption: a review of fundamentals. Journal of Clinical Pharmacology, 42(6),
620-43.
27) van de Waterbeemd,
H. (2005). Which in vitro screens guide the prediction of oral absorption and
volume of distribution? Basic and Clinical
Pharmacology and Toxicology, 96,162–166.
28)
Alavijeh, M.S., Mansoor, C., Zeeshan, Q., & Palmer, A. M. (2005). Drug Metabolism and Pharmacokinetics, the Blood-Brain Barrier, and
Central Nervous System Drug Discovery. Journal
of the American Society for Experimental Neurotherapeutics, 2(4), 554–571.
29) Alcohol
Metabolism in Asian-American Men with Genetic Polymorphisms of Aldehyde
Dehydrogenase. Annals
of Internal Medicine,
127(5), 376-379.
30)
National Alliance on Mental Illness. Treatments and Services. Retrieved from
http://www.nami.org/template.cfm?section=About_Treatments_and_Supports
31) Glick,
I.D., Marder, S., Janowsky, D., Suppes, T., & DeBattista, C. Short- and
Long-Term Psychopharmacological Treatment Strategies. Retrieved from
http://www.acnp.org/g4/GN401000084/CH083.html.
32) Kalachnik, J. E., Leventhal, B. L., James, D. H., Sovner, R., Kastner,
T. A., Walsh, K., & Klitzke, M. G., (1995). Guidelines for the use of
psychotropic medication. International
consensus conference of psychopharmacology. Ohio State University:
Columbus, Ohio.
33) Minnesota Department of
Human Services. History of Psychotropic Medication Use for
Consumers with Developmental Disabilities. Retrieved from
http://www.dhs.state.mn.us/main/groups/licensing/documents/pub/dhs16_157674.pdf.
34) Braun, J. (2000). The Legal Aspects of Chemical Restraint Use in Nursing Homes. Marquette Elder's Advisor, 2 (2). Retrieved
from http://scholarship.law.marquette.edu/cgi/viewcontent.cgi?article=1232&context=elders.
35)
National Alliance on Mental Illness. 2013. Dual Diagnosis: Substance Abuse and
Mental Illness. Retrieved from
http://www.nami.org/Template.cfm?Section=By_Illness&Template=/ContentManagement/ContentDisplay.cfm&ContentID=23049.
36) Towson, M.D., (1993). Outcome based performance measures.
Accreditation Council on Services for People with Disabilities.
37) Northern Territory
Government Australia. An overview of alcohol and other drug uses. Retrieved
from http://www.nt.gov.au/health/healthdev/health_promotion/bushbook/volume2/chap1/sect1.htm.
38) Moncrieff, J. (2006). Why is it so difficult to stop psychiatric drug treatment? It may be
nothing to do with the original problem. Medical
hypotheses, 67(3),
517-23.
39) Wallis, C. & Willwerth, J. (1992).
"Awakenings Schizophrenia a New Drug Brings Patients Back to Life". Time.
40) Iskedjian, M., Hux, M., & Remington, G.J.
(1998). The Canadian experience with
risperidone for the treatment of schizophrenia: an overview. Journal of Psychiatry and
Neuroscience, 23(4),
229–239.
41) Singh, V., Bowden, C.L., & Mintz, J. (2013). Relative effectiveness of adjunctive
risperidone on manic and depressive symptoms in mixed mania. International Clinical
Psychopharmacology, 28(2),91-5. doi: 10.1097/YIC.0b013e32835c7590.
42) Pandina, G.J. (2007).
Risperidone improves behavioral symptoms in children with autism in a
randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 37(2), 367-73.
43) Yatham, L.N., Kennedy,
S.H., Schaffer, A., Parikh, S.V., Beaulieu, S., O'Donovan, C., MacQueen, G.,
McIntyre, R.S., Sharma, V., Ravindran, A., Young, L.T., Young, A.H., Alda, M.,
Milev, R., Vieta, E., Calabrese, J.R., Berk, M., Ha, K., & Kapczinski, F.
(2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) and
International Society for Bipolar Disorders (ISBD) collaborative update of
CANMAT guidelines for the management of patients with bipolar disorder: update
2009. Bipolar Disorder, 11(3), 225-55.
doi: 10.1111/j.1399-5618.2009.00672.x.
44) Schneider, L.S., Dagerman, K.S., & Insel, P.
(2005). Risk of death with atypical antipsychotic drug treatment for dementia:
meta-analysis of randomized placebo-controlled trials. JAMA, 19, 294(15), 1934-43.
45) Tisdale, J.E. (2008). The
effect of intravenous haloperidol on QT interval dispersion in critically ill
patients: comparison with QT interval prolongation for assessment of risk of
Torsades de Pointes. Journal of Clinical
Pharmacology, 41(12), 1310-8.
46) Hesslinger, B. (1999). Effects of carbamazepine and
valproate on haloperidol plasma levels and on psychopathologic outcome in
schizophrenic patients. Journal of
Clinical Psychopharmacology, 19(4), 310-5.
47) Fluoxetine in the
treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind
trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Archives of General Psychiatry, 49(2),
139-47.
48) Garnock-Jones,
K.P., Keating, G.M. (2009). Atomoxetine: a review of its use in
attention-deficit hyperactivity disorder in children and adolescents. Paediatric Drugs, (3), 203-26. doi:
10.2165/00148581-200911030-00005.
49) Haria, M., Fitton, A., & McTavish,
D. (1994). "Trazodone. A review of
its pharmacology, therapeutic use in depression and therapeutic potential in
other disorders". Drugs and Aging,
(4), 331–55. doi:10.2165/00002512-199404040-00006. PMID 8019056.
50) Peck, A.W., Stern, W.C., &
Watkinson, C. (1983). Incidence of seizures during treatment with tricyclic
antidepressant drugs and bupropion. Journal
of Clinical Psychiatry, 44(5 Pt 2), 197-201.
51) Kasper, S., & McEwen, B.S. (2008).
"Neurobiological and clinical effects of the antidepressant
tianeptine". CNS Drugs, 22 (1),
15–26. doi:10.2165/00023210-200822010-00002. PMID 18072812.
52) den Boer, J.A., Bosker, F.J., &
Meesters, Y. (2006). Clinical efficacy of agomelatine in depression: the
evidence. International Clinical
Psychopharmacology, 21 Suppl 1:S21-4.
53) Mayer, G., Meier, E. K., & Hephata,
K. (1995) Selegeline hydrochloride treatment in narcolepsy. A double-blind,
placebo-controlled study. Clinical
Neuropharmacology, 18(4), 306-19.
54) Olkkola, K.T., & Ahonen, J. (2008).
"Midazolam and other benzodiazepines”. Handbook
of Experimental Pharmacology, 182 (182), 335–60.
55) Breimer, D.D., Jochemsen, R., & von
Albert, H.H. (1980). Pharmacokinetics of benzodiazepines. Short-acting versus
long-acting. Arzneimittelforschung,
30(5a), 875-81.
56) Khadke, V.V., Khadke, S.V., &
Khare, A. (2012). Oral propranolol--efficacy and comparison of two doses for
peri-operative anxiolysis. Journal of
Indian Medical Association, 1190(7), 457-60.
57) Zosel, A., Bartelson, B.B., Bailey, E.,
Lowenstein, S., & Dart, R. (2013). Characterization of adolescent
prescription drug abuse and misuse using the Researched Abuse Diversion and
Addiction-related Surveillance (RADARS(®)) System. Journal of American Academy of Child and Adolescent Psychiatry,
52(2), 196-204.e2. doi: 10.1016/j.jaac.2012.11.014. Epub 2013 Jan 5.
58) Negrusz, A., & Gaensslen, R.E.
(August 2003). "Analytical developments in toxicological investigation of
drug-facilitated sexual assault". Analytical
and bioanalytical chemistry, 376 (8), 1192–7.
doi:10.1007/s00216-003-1896-z. PMID 12682705.
59) Josey, E.S., & Tackett, R.L.
(1999). St. John's wort: a new alternative for depression? International Journal of Clinical Pharmacology Therapeutics, 37(3),
111-9.
60) Lecrubier, Y., Clerc, G., Didi, R.,
& Kieser, M.(2002). Efficacy of St. John's wort extract WS 5570 in major
depression: a double-blind, placebo-controlled trial. American Journal of Psychiatry, 159(8), 1361-6.
61)Shelton, R.C.,
Keller MB, Gelenberg A, (2001) Effectiveness of St John's wort in major
depression: a randomized controlled trial. JAMA,
285(15),1978-86.
62) American Society of Hospital
Pharmacists. Medication misadventures: ASHP Guidelines on Adverse Drug Reaction
Monitoring and Reporting. Retrieved from
www.ashp.org/s_ashp/docs/files/MedMis_Gdl_ADR.pdf.
63) Food and Drug Authority. News and
Events (2007). Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108905.htm.
64) Bates, D.W., Spell, N., & Cullen,
D.J. (1997). The costs of adverse drug events in hospitalized patients. JAMA, 277(4), 307-11.
65) Bates, D.W., Cullen, D.J., & Laird,
N.(1995). Incidence of adverse drug events and potential adverse drug events. JAMA, 274(1), 29-34.
66) Evans, R.S., Pestotnik, S.L., Classen,
D.C. (1992). Prevention of adverse drug events through computerized
surveillance. Proc Annual Symposium on
Computer (sic) Applications in Medical Care, 437-41.
67) Lesar TS, Briceland L, Stein DS. (1997)
Factors related to errors in medication prescribing. JAMA, 277(4), 312-7.
68) Leape LL, Bates D.W., Cullen, D.J.
(1995). Systems analysis of adverse drug events. JAMA, 274(1), 35-43.
69) Evans RS, Pestotnik SL, Classen DC, et
al.(1994) Preventing adverse drug events in hospitalized patients. Ann
Pharmacotherapy, 28(4), 523-7.
70) Commonly studied medication errors as
causes of adverse drug events (ADEs): percent of ADEs for each cause: Reducing
and Preventing Adverse Drug Events To Decrease Hospital Costs. March 2001. Agency for Healthcare Research and Quality,
Rockville, MD. http://www.ahrq.gov/research/findings/factsheets/errors-safety/aderia/figure2.html
71) Skrabal, M.Z., Stading, J.A., &
Monaghan, M.S. (2003). Rhabdomyolysis associated with simvastatin-nefazodone
therapy. South Medical Journal,
96(10), 1034-5.
72) Desmarais, J.E. (2009). Interactions between tamoxifen and
antidepressants via cytochrome P450 2D6. Journal of Clinical
Psychiatry, 70(12), 1688-97. doi: 10.4088/JCP.08r04856blu.
73) Onishi, Y., Kato, S., Kobayashi, T.,
Kinuta, T., & Hirai, N. (2005). Remarkably low blood pressure induced by
combination of SSRI and a small dose of TCA. Seishin Shinkeigaku Zasshi, 107(10), 1034-9.
74) Rodriguez, de la
Torre. B., Dreher, J., & Malevany, I., (2001). Serum levels and
cardiovascular effects of tricyclic antidepressants and selective serotonin
reuptake inhibitors in depressed patients. Therapeutic
Drug Monitoring, (4), 435-40.
75) Montejo-González, A.L., Llorca, G.,
& Izquierdo, J.A. (1997). SSRI-induced sexual dysfunction: fluoxetine,
paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and
descriptive clinical study of 344 patients. Journal
of Sex and Marital Therapy, 23(3), 176-94.
76) Ghadirian, A.M., Annable, L., &
Bélanger, M.C. (1992). Lithium, benzodiazepines, and sexual function in bipolar
patients. American Journal of Psychiatry,
149(6), 801-5.
77) Urban, R.J., & Veldhuis, J.D.
(1991). A selective serotonin reuptake inhibitor, fluoxetine hydrochloride,
modulates the pulsatile release of prolactin in postmenopausal women. American Journal of Obstetrics Gynecology,
164(1 Pt 1), 147-52.
78) Lucena, M.I., Carvajal, A., Andrade,
R.J., & Velasco, A. (2003). Antidepressant-induced hepatotoxicity. Expert Opinion on Drug Safety, 2(3),
249-62.
79) Naidoo, U., Goff, D.C., &
Klibanski, A. (2003). Hyperprolactinemia and bone mineral density: the potential impact of
antipsychotic agents. Psychoneuroendocrinology,
28 Supplement 2, 97-108.
80) Bolton, J.M., Targownik, L.E., &
Leung, S. (2011). Risk of low bone mineral density associated with psychotropic
medications and mental disorders in postmenopausal women. Journal of Clinical Psychopharmacology, (1), 56-60. doi:
10.1097/JCP.0b013e3182075587.
81) Correll, C.U., & Schenk, E.M.
(2008). Tardive dyskinesia and new antipsychotics. Current Opinion on Psychiatry, 21(2), 151-6. doi:
10.1097/YCO.0b013e3282f53132.
82) Roerig, J.L., Steffen, K.J., &
Mitchell, J.E. (2011). Atypical antipsychotic-induced weight gain: insights
into mechanisms of action. CNS Drugs,
25(12), 1035-59. doi: 10.2165/11596300-000000000-00000.
83) Johns Hopkins Medicine. Hopkins Scientists Uncover Cause Of
Antipsychotic Drug Weight Gain (2007). Retrieved from http://www.hopkinsmedicine.org/news/media/releases/Hopkins_Scientists_Uncover_Cause_Of_Antipsychotic_Drug_Weight_Gain.
84) American Diabetes Association.
Antipsychotic Medication and the Risk of Diabetes and Cardiovascular Disease.
Retrieved from http://professional.diabetes.org/admin/UserFiles/file/CE/AntiPsych%20Meds/Patient%20Tool%20%233.pdf.
85) Jungi, W.F., Fischer, J., & Senn,
H.J. (1977). Frequent cases of agranulocytosis due to clozapine (leponex) in
eastern Switzerland. Schweiz Med
Wochenschr, 107(49), 1861-4.
86) Tran, P.V., Hamilton, S.H., &
Kuntz, A.J. (1997). Double-blind comparison of olanzapine versus risperidone in
the treatment of schizophrenia and other psychotic disorders. Journal of
Clinical Psychopharmacology, 17(5), 407-418.
87) Goodnick, P.J., Rodriguez, L., &
Santana, O. Antispychotics: impact on prolactin levels. Expert Opinion on Pharmacotherapy. 3, 1381–91.
88) 4) Cornell Cares. Ask Dr. Abrams. Retrieved from http://www.cornellcares.org/ask/fda.html?name1=Archived+Questions&type1=2Select
89) Isaac, R., Boura-Halfon, S., & Gurevitch,
D.(2013). Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin
secretion and action in pancreatic β cells. Journal
of Biology and Chemistry, 288(8), 5682-93. doi: 10.1074/jbc.M112.408641.
Epub 2012 Dec 28.
90) Cutler AJ. (2003). Sexual dysfunction
and antipsychotic treatment. Psychoneuroendocrinology,
28 Supplement 1, 69-82.
91) Christman, A.K., Fermo, J.D., &
Markowitz, J.S. (2004) Atomoxetine, a novel treatment for
attention-deficit-hyperactivity disorder. Pharmacotherapy,
24(8), 1020-36.
92) McKnight, R.F., Adida, M., & Budge,
K. (2012). Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 379(9817), 721-8. doi:
10.1016/S0140-6736(11)61516-X. Epub 2012 Jan 20.
93) Volkow, N.D., Ding, Y.S., Fowler, J.S., Wang, G.J.,
Logan, J., Gatley, J.S., Dewey, S., Ashby, C., Liebermann, J., & Hitzemann,
R. (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics
and distribution in the human brain. Archives of General Psychiatry. 52(6),
456-63.
94) US F.D.A. FDA Adverse Event Reporting System (FAERS) (formerly AERS). Retrieved
from
http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/default.htm.
95) American Psychological
Association. DSM-IV-TR®
Diagnostic and Statistical Manual of Mental Disorders. DOI:
10.1176/appi.books.9780890423349.15861.
96) Concise Medical Dictionary. Schizophrenia.
Oxford University Press. Oxford Reference Online. Maastricht
University Library.
97) Noll, R. (2007). Erotomania. The
Encyclopedia of Schizophrenia and Other Psychotic Disorders (3rd ed.) New York: NY, Infobase.
98) Ravindran, A.V., Yatham, L.N.,
& Munro, A. (1999). Paraphrenia redefined. Canadian Journal of
Psychiatry, 44(2), 133-7.
99) Esterberg, M.L., Goulding, S.M., & Walker, E.F.
(2010). A Personality Disorders: Schizotypal, Schizoid and Paranoid Personality
Disorders in Childhood and Adolescence. Journal of Psychopathology and
Behavioral Assessment, 32(4), 515–528. doi: 10.1007/s10862-010-9183-8.
100) DSM-IV-TR:
The Ten Personality Disorders: Cluster B. Community Counseling Services
Organization. Retrieved from http://www.communitycounselingservices.org/poc/view_doc.php?type=doc&id=564.
101) Blais, M.A., Smallwood, P., Groves, J.E., &
Rivas-Vazquez, R.A. (2008). Personality and personality disorders. In: Stern,
T.A., Rosenbaum, J.F., Fava, M., Biederman, J., & Rauch, S.L. Massachusetts General Hospital Clinical
Psychiatry. 1st ed. Philadelphia, PA: Elsevier Mosby.
102) Johns Hopkins Medicine. Personality disorders.
Retrieved from
http://www.hopkinsmedicine.org/healthlibrary/conditions/mental_health_disorders/personality_disorders_85,P00760/.
103) American Academy of Child and Adolescent
Psychiatry. Resource Centers. Retrieved from
http://www.aacap.org/cs/resource.centers.
104) Akiskal, H. Mood Disorders:
Clinical Features. Kaplan & Sadock’s
Comprehensive Textbook of Psychiatry. Retrieved from http://www.brown.edu/Courses/BI_278/Other/Teaching%20examples/Brain%20and%20Behavior/articles/mood.pdf.
105) Elder, R., Evans, K. & Nizette, D. (2009).
Psychiatric and Mental Health Nursing (2nd ed.). NSW, Australia:
Elsevier.
106) Ballantyne, J.C., Carwood, C., Gupta, A., Bennett,
M.I., Simpson, K.H., Dhandapani, K., Lynch, L., & Baranidharan, G. (2009). Effectiverness of epidural, subarachnoid and
intracerebroventricular opioid drugs to treat patients with pain due to cancer.
Cochrane Database of Systematic
Reviews, (2). DOI: 10.1002/14651858.CD005178.
107) Medscape Reference. Clozapine. Retrieved from
http://reference.medscape.com/drug/clozaril-fazaclo-odt-clozapine-342972.
108) Medscape Reference. Bupropion. Retrieved from http://reference.medscape.com/drug/wellbutrin-zyban-bupropion-342954.
109) Medscape Reference. Lithium. Retrieved from http://reference.medscape.com/drug/eskalith-lithobid-lithium-342934.
110) National Institute of Health. Dose-response
relationships. Retrieved from http://science.education.nih.gov/supplements/nih2/chemicals/guide/pdfs/lesson3.pdf.
111) Muller, P.Y., & Milton, M.N. (2012). The determination and interpretation of the
therapeutic index in drug development. Nature Review, Drug Discovery, 11(10),
751-61. doi: 10.1038/nrd3801. Epub 2012 Aug 31.
112) Bartels, S., & Naslund, J. (2012). The mental health
and substance use workforce for older adults: in whose hands? New England Journal of Medicine.
Retrieved from http://www.nejm.org/doi/full/10.1056/NEJMp1211456#t=article.
113) Bartels
S., Clark R., Peacock W., Dums A., Pratt
S. (2003). Medicare and Medicaid costs for
schizophrenia patients by age cohort compared with costs for depression, dementia,
and medically ill patients. American Journal of Geriatric Psychiatry (11), 648-657.
114) Compton, R. (2012). Polypharmacy Concerns in the Geriatric
Population (PDF document). Retrieved from Virginia Osteopathic Medical
Association. Retrieved from http://voma-net.org/lectures/Fall2012/PolypharmacyConcernsintheGeriatricPopulation.pdf.
115) Whirl-Carrillo, M., McDonagh,
E.M., Hebert, J.M., Gong, L., Sangkuhl, K., Thorn, C.F., Altman, R.B., &
Klein, T.E. (2012). Pharmacogenomics
Knowledge for Personalized Medicine. Clinical
Pharmacology & Therapeutics,
92(4), 414-417.
116) Boyd, M.A. (2008). Principles
of Psychiatric Nursing (106-107). Psychiatric Nursing: Contemporary Practice (4th
ed.). Philadelphia, PA: Lippincott Williams & Wilkins.
117) Unger, J., Decaux, G.,
L'Hermite, M. (1982). Rhabdomyolysis, acute renal failure, endocrine
alterations and neurological sequelae in a case of lithium self poisoning. Acta Clinica Belgica, 37, 216-33.
118) Apte, S.N., Langston, J.W. (1983). Permanent neurological deficits due
to lithium toxicity. Ann Neurol,13,
453-5.
119) Seniors and Phenytoin. In
Professionals/Epilepsy online. Retrieved from http://professionals.epilepsy.com/medications/a_phenytoin_seniors.html.
120) Women’s Mental Health
Organization. Psychiatric Disorders During Pregnancy (n.d.). Retrieved March
28, 2013, from http://www.womensmentalhealth.org/specialty-clinics/psychiatric-disorders-during-pregnancy/.
121) Salvatore, G. (2010). Antipsychotic Therapy During Early and Late
Pregnancy: A Systematic Review. Schizophrenia
Bulletin: Oxford Journals, 36(3), 518–544. Retrieved March 28, 2013, from
Pubmed.
122) Reynolds, G.P. & Kirk, S.L. (2010). Review Metabolic side effects of antipsychotic drug
treatment--pharmacological mechanisms. Pharmacology
and Therapeutics, 125(1),
169-79.
123) Coccurello, R.,
& Moles, A. (2010). Review Potential
mechanisms of atypical antipsychotic-induced metabolic derangement: clues for
understanding obesity and novel drug design. Pharmacology and
Therapeutics, 127(3),210-51.
124) Women’s Mental Health Organization. Lithium and Breastfeeding
(n.d.). Retrieved March 28, 2013, from http://www.womensmentalhealth.org/posts/lithium-and-breastfeeding/.
125)
American College of Obstetricians and
Gynecologists (ACOG) (2008). Use of psychiatric medications during pregnancy
and lactation. Retrieved March 28, 2013 from http://guideline.gov/content.aspx?id=12490.
126) Stanford School of Medicine: Center for Neuroscience in
Women’s Health (n.d.). Pregnancy and Mental Health. Retrieved March 28, 2013
from http://womensneuroscience.stanford.edu/wellness_clinic/Pregnancy.html.
127) Kieler,H.,Artama, M., Engeland, A., Ericsson, O.,
Furu, K., Gissler, M., Beck,
R., Nørgaard, M., Stephansson, O., Valdimarsdottir, U., Zoega, H., Haglund, B.
(2012). Selective serotonin reuptake
inhibitors during pregnancy and risk of persistent pulmonary hypertension in
the newborn: population based cohort study from the five Nordic countries. British
Medical Journal, 344, d8012. Retrieved March 29, 2013, from BMJ database.
128) Pidano, A. (2012). Pediatric
Psychopharmacology: Context, Model Programs, and Considerations for Care. Psychiatric
Services 2012, doi: 10.1176/appi.ps.201100318.
129) Correll, C.U., Kratochvil, C.J., & March,
J.S. (2011). Developments
in pediatric psychopharmacology: focus on stimulants, antidepressants, and
antipsychotics. Journal of Clinical Psychiatry, 2011 May, 72(5), 655-70, doi: 10.4088/JCP.11r07064.
130) Wall,
C., Oldenkamp,C. & Swintak, C. (2010). Safety
and Efficacy Pharmacogenomics in Pediatric Psychopharmacology. Primary
Psychiatry, 2010, 17(5), 53-58.
131) Thomas, C.R., & Holzer,
C.E. (2006). The continuing shortage of child and adolescent psychiatrists. Journal of American Academy of Child
Adolescent Psychiatry, 45(9),1023-1031.
132) Approval supports
antipsychotic use in children with schizophrenia or bipolar disorder. The
Journal of Family Practice November 2007, 6(11).
133) Geller, D.A. New Advances in
the Psychopharmacological Treatment of Obsessive Compulsive Disorder. American Academy of Child and Adolescent
Psychiatry. Retrieved from http://www.aacap.org/cs/root/developmentor/new_advances_in_the_psychopharmacological_treatment_of_obsessive_compulsive_disorder.
134)
Giardino, A.P. (2012). Pediatric Depression Treatment & Management.
Retrieved from http://emedicine.medscape.com/article/914192-treatment#aw2aab6b5b4.
135) Taketomo, C.K., Hodding, J.H., & Kraus, D.M. Pediatric Dosage Handbook,
7. Hudson, Ohio: Lexi-Comp, Inc. 2000.
136) Vitiello, B. (2008). An
international perspective on pediatric psychopharmacology. International
Review of Psychiatry, 2008 Apr, 20(2), 121-6. doi:
10.1080/09540260801887710.
137) Punja,
S., Zorzela,
L., Hartling,
L., Urichuk,
L., & Vohra,
S. (2013). Long-acting versus short-acting methylphenidate for paediatric ADHD:
a systematic review and meta-analysis of comparative efficacy. British
Medical Journal Open, 3:e002312. doi:10.1136/bmjopen-2012-002312.
138) Greydanus, D.E., Nazeer, A., Patel, D.R. (2009). Psychopharmacology of ADHD
in pediatrics: current advances and issues. Neuropsychiatric Disease and
Treatment, 2009, (5), 171–181.
139) Lisska, M.C., Rivkees, S.A. (2011). Daily
Methylphenidate Use Slows the Growth of Children: A Community Based Study. Journal of Pediatric Endocrinology and
Metabolism, 16(5), 711–718.
DOI: 10.1515/JPEM.2003.16.5.711.
140)
Food and Drug Authority. (2002). Cylert®. 03-5228-R21-Rev. December, 2002.
Rockville, MD: US Government. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/016832s022_017703s018lbl.pdf.
141)
Charlton, B.G. (2003). Palliative
psychopharmacology: a putative speciality to optimize the subjective quality of
life. Oxford Journal of Medicine. 96 (5), 375-378.
doi: 10.1093/qjmed/hcg055.
142) NCHS Data Brief. (2011). Antidepressant Use
in Persons Aged 12 and Over: United States, 2005–2008. Retrieved from http://www.cdc.gov/nchs/data/databriefs/db76.htm.
143) Cushing,
T. A., Benzer, T.I. Selective Serotonin Reuptake Inhibitor Toxicity (2012). Medscape.
Retrieved from http://emedicine.medscape.com/article/821737-overview#aw2aab6b2b2aa.
144) Mason, P.J., Morris, V.A., & Balcezak, T.J.
Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore), Jul
2000, 79(4):201-9.
145)
Hawton, K., Bergen, & H., Simkin, S. (2010). Toxicity of antidepressants:
rates of suicide relative to prescribing and non-fatal overdose. British Journal
of Psychiatry (2010), 196(5), 354–358, doi: 10.1192/bjp.bp.109.070219.
146)
Gillman, P.K. Monoamine oxidase inhibitors, opioid analgesics and serotonin
toxicity. British Journal of Anaesthesia (2005),95(4),434-441.
147)
Tsai, V. (2012). Tricyclic Antidepressant Toxicity in Emergency Medicine. Medscape.
Retrieved from http://emedicine.medscape.com/article/819204-overview#a0199.
148) Bronstein, A.C., Spyker, D.A., Cantilena, L.R., Green,
J.L., Rumack, B.H., & Heard, S.E. 2007 Annual Report of the American
Association of Poison Control Centers' National Poison Data System (NPDS): 25th
Annual Report. Clinical Toxicology (Philadelphia). Dec 2008, 46(10):927-1057.
149)
Wille, S.M., Cooreman, S.G., Neels, H.M., & Lambert, W.E. (2008). Relevant
issues in the monitoring and the toxicology of antidepressants. Critical
Reviews in Clinical Laboratory Sciences, 45(1), 25-89.
150)
Marcus, S. (2013). Toxicity MAOIs: Clinical. Medscape Pharmacists Education.
Retrieved from http://www.medscape.org/viewarticle/727349_2.
151)
Lafferty, K. (2012). Barbiturate toxicity. Medscape. Retrieved from http://emedicine.medscape.com/article/813155-overview#a0104.
152)
Woods, J., Katz, J. & Winger, G. Abuse and Therapeutic Use of
Benzodiazepines and Benzodiazepine-Like Drugs. American College of
Neuropsychopharmacology. Retrieved from http://www.acnp.org/g4/GN401000172/CH168.html.
153)
Lee, D.C. (2010). Lithium Toxicity. Medscape. Retrieved from http://emedicine.medscape.com/article/815523-overview#a0104.
154)
Roberts, L.W., Mental Illness and Informed Consent: Seeking an Empirically
Derived Understanding of Voluntarism. Current
Opinion in Psychiatry, 2003, 16(5).
155)
Candia, P., & Barba, A. (2011). Mental Capacity and Consent to Treatment in
Psychiatric Patients. Current Opinion in
Psychiatry, 24(5), 442-446.
156)
Menninger, J.A. Involuntary treatment: Hospitalization and medication. Brown University. Retrieved from http://www.brown.edu/Courses/BI_278/Other/Clerkship/Didactics/Readings/INVOLUNTARY%20TREATMENT.pdf.
157)
National Institute on Drug Abuse. Monitoring the future: national results on
adolescent drug use. 2011. Retrieved from http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2011.pdf.
158)
National Library of Medicine. Drug dependence. Retrieved from http://www.nlm.nih.gov/medlineplus/ency/article/001522.htm.
160)
McHenry, L. Ethical issues in psychopharmacology. Journal of Medical Ethics. 2006 July, 32(7), 405–410,
doi: 10.1136/jme.2005.013185.
161)
Ashcroft, G. The receptor enters psychiatry: The
psychopharmacologists (3). London: Arnold, 2000, 194.
162)
Smith, D.C. Antidepressant efficacy. Ethical Human Sciences and Services,
2000. 2(3), 215–216.
163)
Medawar, C. The antidepressant web: marketing depression and making
medicines work. International Journal of Risk and Safety in Medicine,
1997, 1086–91.
164)
Teicher, M.H., Glod, C., & Cole, J.O. Suicidal preoccupation during
fluoxetine treatment. American Journal of Psychiatry, 147,
1380–1381.
165) Masand,
P., Gupata, S., & Dewan, M. Suicidal ideation related to fluoxetine
treatment. New England Journal of Medicine, 1991, 324420.
166)
Centers for Medicare and Medicaid Services. Medicare and your mental health
benefits. Retrieved from http://www.medicare.gov/pubs/pdf/10184.pdf.
167)
American Psychological Association. Health and homelessness. Retrieved from http://www.apa.org/pi/ses/resources/publications/homelessness-health.aspx.
168)
Johns Hopkins Institute for Policy Studies. The severely mentally ill homeless:
housing needs and housing policy. Retrieved from http://ips.jhu.edu/pub/The-Severely-Mentally-Ill-Homeless-Housing-Needs-and-Housing-Policy.
169)
New York State Office of Alcoholism and Substance Abuse Services. Patient
Advocacy Brochure. Retrieved from http://www.oasas.ny.gov/publications/pdf/PatientAdvocacyBrochure.pdf.
170)
Pathways to promise. Impact of Mental Illness on Families. Retrieved from http://www.pathways2promise.org/family/impact.htm.
171)
American Psychiatric Association. Practice Guideline for the Treatment of
Patients With Schizophrenia Second Edition. Retrieved from http://psychiatryonline.org/content.aspx?bookid=28§ionid=1665359#48535.
172)
Dixon, L., Goldman, H., & Hirad, A. State
policy and funding of services to families of adults with serious and
persistent mental illness. Psychiatric
Service 1999, 50,551–553 [G] 1007838.
173)
National Alliance on Mental Illness. NAMI CBT Factsheet. Retrieved from http://www.nami.org/factsheets/CBT_factsheet.pdf.
174)
Canadian Counseling and Psychotherapy Association. Types of Psychotherapy:
Psychodynamic vs. Cognitive-behavioral. Retrieved from http://www.ccpa-accp.ca/blog/?p=452.
175)
Wright, B., Williams, C., & Garland, A. 2002. Using the Five Areas cognitive–behavioral therapy model with psychiatric
patients. Advances in Psychiatric
Treatment (2002),8,307-315. doi:10.1192/apt.8.4.307.
176)
Slavson, S.R. Types of Group Psychotherapy and Their Clinical Applications,
Part 1. American Mental Health Foundation. Retrieved from http://americanmentalhealthfoundation.org/a.php?id=31.
177)
Counseling Center. Group Counseling. University
of Chicago. Retrieved from http://www.counselingcenter.illinois.edu/?page_id=37.
178)
Tool Kit Sport Development Organization. Community-based psychological
support-module 1. Retrieved from http://www.toolkitsportdevelopment.org/html/resources/2C/2C4783F0-083B-4382-8DED-D99AEC37B0F2/pspmanual_module1.pdf.
179)
National Alliance on Mental Illness. Helpful tips for families. Retrieved from http://www.namiyolo.org/tipsforfamilies.html.
180)
The Center for Reintegration. Mental Illness and the Workplace. Retrieved from http://www.reintegration.com/reint/employment/workplace.asp.
181)
Equal Employment Opportunity Commission. The ADA: Your Employment Rights as an Individual With a Disability. Retrieved
from http://www.eeoc.gov/facts/ada18.html.
182) Out
of the Shadows at Last: Transforming Mental Health, Mental Illness
and Addiction Services in Canada, 8. The Parliament of Canada.
Retrieved from http://www.parl.gc.ca/Content/SEN/Committee/391/soci/rep/rep02may06part3-e.htm.
183) Community-Based Treatment of Schizophrenia
and Other Severe Mental Disorders: Treatment Outcomes. Medscape General
Medicine. 2001, 3(1) .
Retrieved from http://www.medscape.com/viewarticle/430529_6.
184) Gowen, K., Deschaine, M., Gruttadara,
D. & Markey, D. Young adults with mental health conditions and social
networking websites: Seeking tools to build community. Psychiatric
Rehabilitation Journal 35.3 (2012), 245-50.
185)
University of Washington. Facts about mental illness and violence. Retrieved
from http://depts.washington.edu/mhreport/facts_violence.php.
186)
Institute of Medicine, Improving the Quality of Health Care for Mental and
Substance-Use Conditions. Washington, DC: Institute of Medicine, 2006.
187)
American Psychiatric Association. (1994). Fact Sheet: Violence and Mental
Illness. Washington, DC: American Psychiatric Association.
188)
Pescosolido, B.A., Monahan, J. Link, B.G. Stueve, A., & Kikuzawa, S.
(1999). The public’s view of the competence, dangerousness, and need for legal
coercion of persons with mental health problems. American Journal of Public
Health, 89, 1339-1345.
189) New
Freedom Commission on Mental Health, Achieving the Promise: Transforming
Mental Health Care in America. Final Report. DHHS Pub. No. SMA-03-3832.
Rockville, MD: 2003.
190)
Mental Health America. American Opinions on Mental Health Issues.
Alexandria: NMHA, 1999.
191) Yoon, J.H., Minzenberg, M.J., Raouf, S.,
D’Esposito, M., & Carter, C.S. (2013). Impaired Prefrontal-Basal Ganglia
Functional Connectivity and Substantia Nigra Hyperactivity in Schizophrenia. Biological
Psychiatry.
192) Schobel, S.A., Chaudhury, N.A., Khan, U.A., Paniagua,B., Styner, M.A.,
Asllani, I., Inbar, B.P., Corcoran, C.M, Lieberman, J.A., Moore, H., &
Small, S.A. (2013). Imaging Patients with Psychosis and a Mouse Model
Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates
Glutamate as a Driver. Neuron, 78(1), 81-93.
193) Stein, D.J., Phillips, K.A., Bolton, D., Fulford, K.W.M., Sadler, J.Z. & Kendler, K.S. (2010). What is a Mental/Psychiatric Disorder? From
DSM-IV to DSM-V. Psychological Medicine, 40(11), 1759–1765. doi: 10.1017/S0033291709992261.
194) Medscape. Methylphenidate.
Retrieved from http://reference.medscape.com/drug/ritalin-sr-methylphenidate-342999.
195) Gillman, P.K. (2011). Monoamine Oxidase Inhibitors
(MAOI), Dietary Restrictions, Tyramine, Cheese and Drug Interactions. MAOIs & Dietary Tyramine, 2(2):1.
Retrieved from http://psychotropical.com/pdfs/maois_diet_full.pdf.
196) Medscape. Atomoxetine. Retrieved from
http://reference.medscape.com/drug/strattera-atomoxetine-342994.
197) Medscape. Mirtazapine. Retrieved from
http://reference.medscape.com/drug/remeron-soltab-mirtazapine-342966
198) Medscape. Venlafaxine. Retrieved from
http://reference.medscape.com/drug/effexor-venlafaxine-342963.
199) Waknine, Y. (2010). FDA Approves Trazodone
Extended-Release Formulation for Depression. Medscape. Retrieved from http://www.medscape.com/viewarticle/716502.
200) Medscape. Trazodone. Retrieved from
http://reference.medscape.com/drug/oleptro-trazodone-d-342965.
201) Medscape. Amitriptyline. Retrieved from http://reference.medscape.com/drug/levate-amitriptyline-342936.
202) Medscpae. Diazepam. Retrieved from http://reference.medscape.com/drug/valium-diastat-diazepam-342902.
204) National Alliance on Mental Illness. Mental
Illnesses. Retrieved from http://www.nami.org/template.cfm?section=about_mental_illness.
205) Jemionek, J.F., Copley, C.L., Smith, M.L., & Past, M.R. (2008). Concentration distribution of the marijuana
metabolite Delta9-tetrahydrocannabinol-9-carboxylic acid and the cocaine
metabolite benzoylecgonine in the department of defense urine drug-testing
program. Journal of Analytical Toxicology, 32(7), 10A-11A.
206) Medscape. Atypical antipsychotics in bipolar
disorder. Retrieved from http://www.medscape.org/viewarticle/554128.
207) Khalil, B.R. & Richa, S. (2011). Thyroid adverse effects of psychotropic
drugs: a review. Clinical Neuropharmacology, 34(6), 248-55. doi:
10.1097/WNF.0b013e31823429a7.
208) Greene, J. (2006). Psychiatrist duties: Tarasoff.
Retrieved from http://www.stanford.edu/group/psylawseminar/Tarasoff.Greene.htm.
209) Amenson, C. Helpful Family Attitudes and Skills. National Institute of Mental Illness.
Retrieved from http://www.namiyolo.org/tipsforfamilies.html.
